10x Genomics v Vizgen (CFI, 22 October 2023)
| Date | 22 October 2023 |
|---|---|
| Court | CFI |
| Division | Hamburg (DE) Local Division |
| Type of action | Application Rop 333 |
| Registry reference | App_49415/2024 · ORD_49705/2024 |
| Parties | 10x Genomics, Inc., President and Fellows of Harvard College, v. Vizgen, Inc. |
Official decision (PDF) · UPC registry entry
Dhenne Avocats represents claimants and defendants in European patent disputes before the Unified Patent Court, including the Paris divisions.
Dhenne Avocats · 10 October 2026
Our analysis
Summary
By an order of 22 October 2024 (UPC_CFI_22/2023, ACT_460565/2023, ORD_49705/2024), the Hamburg Local Division (S. Klepsch, presiding judge and judge-rapporteur, S. Schilling, M. Kokke, and A. Burrichter, technically qualified judge), on Vizgen, Inc.’s application for review under Rule 333 RoP in the action brought by 10x Genomics, Inc. and the President and Fellows of Harvard College for infringement of EP 4 108 782, varied the judge-rapporteur’s order of 15 August 2024: the claimants must produce emails, an internal FAQ document and a deposition transcript from the parallel proceedings before the Delaware court. Leave to appeal was granted.
Question
Is an order for the production of documents under Rule 190 RoP open to review by the panel, and does an abuse-of-rights defence justify production of documents from the US proceedings?
Decision
A production order is a case management decision and may be reviewed under Rule 333.1 RoP. Abuse of rights may be raised before the UPC if it relates to the contractual relationship and the subject matter of the claims. The emails may support the inference that 10x Genomics acquired and expanded its position to push out competitors, with Harvard’s knowledge, and the FAQ document that the litigation was used to unsettle customers: their production is ordered. The request concerning sales below cost is rejected, predatory pricing being a matter for competition authorities and courts. As the documents already exist in the US proceedings, production is not disproportionate, and Vizgen need not first use the 35 U.S.C. § 1782 procedure. The documents are restricted to outside attorneys registered in the CMS, to the exclusion of the parties’ employees.
Key points for practice
- Practical point: an abuse-of-rights defence may open access before the UPC to documents produced in US proceedings, under a confidentiality regime limited to outside attorneys.
Provisions applied
- Agreement on a Unified Patent Court
- Art. 1(1), Art. 59(1) and Art. 73(2)(b)
- Rules of Procedure
- Rules 190, 191, 220.2, 224.1(b), 262A and 333
- Regulation (EU) No 1257/2012
- Art. 5(3)
- Case law cited
- Plant-e v Arkyne, The Hague Local Division, 4 March 2024
Prepared by Dhenne Avocats from the official decision, consulted on 10 October 2026. The database is updated every week, on Friday. Only the official text is authoritative.
Going further
Lexicon: Written procedure (UPC).
Source and translations
- Official source
- Unified Patent Court registry link recorded in the record
- Original language
- not recorded
- Translation available
- no translation recorded the firm’s French record is a summary, not a translation
- Date checked
- not recorded
Follow this case
Proceedings, related decisions, appeals, parties and patents as recorded in the registry and in the Dhenne Avocats corpus. Each link states its source.
Proceedings
Parties
- claimant10x Genomics, Inc.57 decisions in the corpusFollow this party
- claimantPresident and Fellows of Harvard College29 decisions in the corpusFollow this party
- defendantVizgen, Inc.6 decisions in the corpusFollow this party
Decisions in the same proceedings and documented appeals
What the record states
- Nature of the act
- Application Rop 333
- Outcome (Dhenne Avocats summary)
- La formation ordonne aux demanderesses de produire des courriels, un document de questions-réponses et une transcription de déposition utiles à la défense d'abus de droit, sous confidentialité réservée aux avocats extérieurs. La demande relative aux ventes à perte est rejetée et l'appel autorisé.
- Appeal
- No appeal documented in the corpus, this does not mean that no appeal was lodged.
- Instance
- First-instance decision, whether it has become final is not recorded.
Patents mentioned
EP 4 108 782mentioned in: Dhenne Avocats analysis Follow this patent
Related decisions cited in the analyses
- Plant-e Knowledge v Arkyne Technologies (CFI, 4 March 2024) cited in this record
Patents and standards
| Publication | Role in the dispute | Family | Standard and declaration | Pool | Sources |
|---|---|---|---|---|---|
EP 4 108 782Compositions and methods for analyte detection recorded proprietor: Harvard University | Mentioned in the analysis (role not qualified) Also mentioned in 18 other decision(s): NanoString Technologies v 10x Genomics (CoA, 11 March 2024) · 10x Genomics v NanoString (CFI, 19 September 2023) · 10x Genomics v Bruker Spatial Biology (CFI, 11 April 2025) · 10x Genomics v Vizgen (CoA, 11 March 2025) · 10x Genomics v Vizgen (CoA, 5 March 2025) · 10x Genomics v Vizgen (CFI, 20 December 2024) · NanoString Technologies v 10x Genomics (CoA, 10 December 2024) · 10x Genomics v Vizgen (CFI, 1 November 2024) | not recorded | not recorded | not recorded | Espacenet · European Patent Register existence and title of the publication checked on 30 October 2026 (Google Patents, Espacenet and Register links are not checked automatically) mentioned in: Dhenne Avocats analysis |
Receive an alert
Weekly summary of new records and substantive updates matching what you follow. Address confirmed by email, unsubscribe at any time, one email per week even where several of your follows match.